BCN HEALTH will present two communications at the Jornadas AES in June in Madrid

One of the presentations will cover the results of a systematic review on the costs and cost-effectiveness of adoptive cell therapy using tumor-infiltrating lymphocytes (TIL-ACT) combined with high-dose interleukin-2 (HD-IL-2) in patients with melanoma in Europe. The aim was to assess healthcare resource use, direct and indirect costs, and economic outcomes associated with this therapy. To this end, literature published between 2000 and 2024 was reviewed. The study concluded that TIL-ACT with HD-IL-2 is a cost-effective treatment option for advanced melanoma, with potential for broader application. However, challenges such as high manufacturing costs and limited geographic data were identified, highlighting the need for further research to support its adoption across different healthcare systems.

The second communication will present an analysis of the economic burden of heart failure in Europe. Based on a review of studies published during the same period (2000–2024), the study assessed cost variability, resource utilization, and the efficiency of management strategies. Findings indicate that hospitalizations remain the main cost driver in the treatment of heart failure. The study also emphasizes that improved risk stratification, the implementation of innovative care models, and the integration of advanced technologies can optimize resource use, enhance cost-effectiveness, and reduce the economic burden of the disease. These findings reinforce the value of personalized interventions within healthcare systems.